![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
Company Announcement, Helsinki, 17 October 2022 at 2 PM (EEST)
Nexstim Plc: Share subscriptions based on stock options 2020A
Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) broadcasts that between 1 July and 30 September 2022, a complete of 21,264 Nexstim Plc’s new shares has been subscribed for with the corporate’s stock options 2020A. For subscriptions made with the stock options 2020A, the whole subscription worth of EUR 42,528.00 shall be entered within the reserve for invested unrestricted fairness. The Company’s share capital is EUR 80,000.00 after the subscription.
After the commerce registration the entire quantity of shares is 6,715,019. The new shares symbolize roughly 0.32 per cent of all of the shares within the Company after the registration.
The shares subscribed for beneath the stock options 2020A have been registered within the Trade Register on 17 October 2022, as of which date the brand new shares will set up shareholder rights.
The shares shall be traded within the Nasdaq Helsinki Plc’s First North Growth Market Finland market as a further lot with the corporate’s outdated shares as of 18 October 2022.
The phrases and circumstances of stock possibility packages with further data can be found on the corporate’s web site at https://www.nexstim.com/investors/.
Further data is out there on the web site www.nexstim.com, or by contacting:
Leena Niemistö, Chair of Board of Directors
+358 9 2727 170
[email protected]
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally working growth-oriented medical know-how firm. Our mission is to allow customized and efficient diagnostics and therapies for difficult mind illnesses and issues.
Nexstim has developed a world-leading non-invasive mind stimulation know-how for navigated transcranial magnetic stimulation (nTMS) with extremely subtle 3D navigation offering correct and customized concentrating on of the TMS to the precise space of the mind.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the one FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the mind.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for advertising and business distribution for the therapy of main depressive dysfunction (MDD) within the United States. In Europe, the NBT® system is CE marked for the therapy of main despair and continual neuropathic ache.
Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For extra data, please go to www.nexstim.com
- Company announcement_Share subscriptions stock options_17102022_EN_FINAL
